Recro Pharma

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. Our lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo controlled trial demonstrating pain relief. We have studied various dosage forms of Dex in eight completed clinical studies, two of which were placebo controlled trials that demonstrated meaningful pain relief. As our product candidates are not opioid based drugs, we expect to overcome many of the side effects associated with commonly prescribed opioid based therapeutics, including addiction, constipation and respiratory distress while maintaining analgesic, or pain relieving, effect. We are ready to begin a Phase IIb trial with Dex in patients experiencing post-operative pain. We believe Dex will become an alternative pain medication to opioids for the more than 50 million surgical procedures that require post-operative pain medication. If approved, Dex would also be the first and only approved post-operative pain drug in its class of drugs.
Company Growth (employees)
Type
Public
HQ
Malvern, US
Size (employees)
195 (est)+5%
Recro Pharma is headquartered in Malvern, US

Recro Pharma Office Locations

Recro Pharma has an office in Malvern
Malvern, US (HQ)
490 Lapp Rd

Recro Pharma Data and Metrics

Recro Pharma Financial Metrics

Recro Pharma's revenue was reported to be $18.7 m in Q1, 2017
USD

Revenue (Q1, 2017)

18.7 m

Gross profit (Q1, 2017)

8.2 m

Gross profit margin (Q1, 2017), %

44%

Net income (Q1, 2017)

(8.1 m)

EBIT (Q1, 2017)

(7.3 m)

Market capitalization (15-Aug-2017)

141.5 m

Cash (31-Mar-2017)

19.5 m
Recro Pharma's current market capitalization is $141.5 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

52 m69.3 m

Revenue growth, %

33%

Cost of goods sold

28.1 m37.2 m

Gross profit

23.9 m32.2 m

Gross profit Margin, %

46%46%

R&D expense

7.9 m12.3 m33.3 m

General and administrative expense

4 m13 m12.7 m

Operating expense total

11.9 m58.9 m95.1 m

EBIT

(11.9 m)(7 m)(25.8 m)

EBIT margin, %

(13%)(37%)

Interest expense

(4.3 m)(5.6 m)(5.6 m)

Interest income

10.5 k12 k49 k

Pre tax profit

(16.1 m)(12.5 m)(31.3 m)

Income tax expense

15.6 m1.1 m

Net Income

(16.1 m)3 m(30.2 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

18.7 m16.5 m17.7 m17.3 m17 m18.7 m

Cost of goods sold

9.4 m10 m10.3 m9.5 m5.7 m10.5 m

Gross profit

9.3 m6.5 m7.5 m7.7 m11.2 m8.2 m

Gross profit Margin, %

50%39%42%45%66%44%

R&D expense

1.8 m3.6 m1.8 m2.8 m2.7 m7.8 m8.3 m7 m7.8 m

General and administrative expense

958.6 k1.1 m2.4 m2.6 m3.5 m2.7 m2.8 m3.8 m4 m

Operating expense total

2.8 m4.7 m4.1 m5.4 m6.2 m10.5 m11.1 m10.9 m11.8 m

EBIT

373 k(164 k)(5 m)(6.8 m)(3.9 m)(7.3 m)

EBIT margin, %

2%(1%)(28%)(39%)(23%)(39%)

Interest expense

(4.3 m)(1.7 m)(2 m)(1.5 m)(1.3 m)(1.5 m)(1.2 m)

Interest income

2.3 k4.6 k3.7 k4 k2 k9 k8 k10 k105 k

Pre tax profit

(6.5 m)(8.1 m)(5.4 m)(8.4 m)

Income tax expense

(11 k)195 k(18 k)293 k

Net Income

(7.9 m)(12.7 m)(4.1 m)(5.5 m)(7.6 m)(6.5 m)(14.4 m)(19.8 m)(8.1 m)
USDFY, 2014FY, 2015FY, 2016

Cash

19.7 m19.8 m64.5 m

Accounts Receivable

89.6 k8.6 m10.4 m

Inventories

9 m1.1 m

Current Assets

20.4 m38.7 m84.8 m

PP&E

37.9 m37.3 m

Goodwill

6.4 m6.4 m

Total Assets

20.4 m138.7 m183 m

Accounts Payable

869.9 k1.6 m4.1 m

Total Debt

11.9 m29.8 m24.4 m

Current Liabilities

1.4 m9.5 m16.3 m

Total Liabilities

111.4 m

Common Stock

77.1 k92 k190 k

Additional Paid-in Capital

52.9 m71.3 m132.7 m

Retained Earnings

(34.1 m)(31.1 m)(61.3 m)

Total Equity

18.9 m40.4 m71.6 m

Debt to Equity Ratio

0.6 x0.7 x0.3 x

Debt to Assets Ratio

0.6 x0.2 x0.1 x

Financial Leverage

1.1 x3.4 x2.6 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

27.8 m23.9 m16.6 m15.7 m28.3 m14.9 m14.8 m24.8 m19.5 m

Accounts Receivable

86.8 k80.2 k15 m9.6 m12.2 m11.5 m12.4 m12.3 m

Inventories

9.6 m8.6 m7.6 m6.7 m9.8 m7.8 m

Current Assets

28.1 m24.1 m17.3 m42.4 m48.4 m36.2 m35.2 m49 m77.3 m

PP&E

39.4 m38.7 m37 m36.6 m36.5 m37.3 m

Goodwill

6.7 m6.7 m6.4 m6.4 m6.4 m6.4 m

Total Assets

28.1 m24.1 m17.9 m129.8 m134.5 m135.1 m133.7 m146 m176.1 m

Accounts Payable

400.2 k682.2 k552.7 k767 k781 k2 m1.8 m1.9 m3 m

Current Liabilities

1.3 m1.9 m2.6 m15.8 m19.1 m12.5 m12.4 m11.3 m12.9 m

Additional Paid-in Capital

52.6 m52.7 m53.5 m54.2 m70 m72.6 m76.7 m91.4 m133.6 m

Retained Earnings

(25.9 m)(30.6 m)(38.2 m)(39.5 m)(41.7 m)(37.6 m)(45.5 m)(50.9 m)(69.4 m)

Total Equity

26.8 m22.2 m15.3 m14.7 m28.4 m35 m31.3 m40.6 m64.4 m

Financial Leverage

1 x1.1 x1.2 x8.8 x4.7 x3.9 x4.3 x3.6 x2.7 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(16.1 m)3 m(30.2 m)

Depreciation and Amortization

1.4 k4.1 m5 m

Accounts Receivable

(51.2 k)4 m(1.8 m)

Inventories

1.3 m(325 k)

Accounts Payable

1.1 m2.2 m8.5 m

Cash From Operating Activities

(10.9 m)8.5 m(3.2 m)

Purchases of PP&E

(2.4 m)(3.8 m)

Cash From Investing Activities

(55.1 m)(3.8 m)

Long-term Borrowings

(16.3 m)(6.3 m)

Cash From Financing Activities

30.5 m46.7 m51.7 m

Interest Paid

4.9 m4.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7.9 m)(12.7 m)(4.1 m)(5.5 m)(7.6 m)(6.5 m)(14.4 m)(19.8 m)(8.1 m)

Depreciation and Amortization

1.3 m2.7 m1.3 m2.5 m3.8 m1.2 m

Accounts Receivable

38.4 k(48.4 k)9.4 k(1.9 m)

Inventories

345 k1.4 m1.3 m2.3 m(830 k)936 k

Accounts Payable

988.5 k1.6 m532.7 k4 m2.7 m2.6 m1.9 m4.5 m(2.4 m)

Cash From Operating Activities

(2.7 m)(6.6 m)(3 m)1.7 m7.8 m(2.4 m)(5.4 m)(4.2 m)(7.1 m)

Purchases of PP&E

(1.2 m)(1.8 m)(344 k)(1.1 m)(2 m)(1.7 m)

Cash From Investing Activities

(53.9 m)(54.5 m)(344 k)(1.1 m)(2 m)(37.9 m)

Long-term Borrowings

(2.6 m)

Cash From Financing Activities

30.5 m30.5 m(125 k)48.2 m55.2 m(2.1 m)1.5 m11.2 m(2.1 m)

Interest Paid

3.4 m1.2 m2.4 m3.5 m1 m
USDY, 2017

Revenue/Employee

98.4 k

Financial Leverage

2.7 x

Recro Pharma Operating Metrics

FY, 2016

Patents Issued

13

Recro Pharma Market Value History

Recro Pharma Revenue Breakdown

Traffic Overview of Recro Pharma

Recro Pharma News and Updates

BRIEF-Recro Pharma Q2 loss per share $0.83

* Sees FY 2016 revenue $55 million to $60 million Source text for Eikon: Further company coverage:

Recro Pharma Company Life and Culture

You may also be interested in